Identifying potential repurposable medications for Parkinson's disease through Mendelian randomization analysis

被引:0
作者
Wang, Qitong [1 ]
Liu, Fang [1 ]
Wang, Xinyu [1 ]
Zhong, Lifan [1 ]
Cai, Benchi [1 ]
Chen, Tao [1 ,2 ]
机构
[1] Hainan Med Univ, Hainan Affiliated Hosp, Hainan Gen Hosp, Dept Neurol, Haikou 570311, Hainan, Peoples R China
[2] Hainan Prov Bur Dis Prevent & Control, Haikou 570100, Peoples R China
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
基金
中国国家自然科学基金;
关键词
Medication; Parkinson's disease; Mendelian randomization; Genetic epidemiology; TRIAL; DISORDERS; CALCIUM; NEURONS;
D O I
10.1038/s41598-024-70758-z
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Observational studies have suggested the potential benefits of several medications for Parkinson's disease (PD) and their potential for repurposing. However, the conclusions drawn from these studies are not entirely consistent. To address this inconsistency, we used the two-sample Mendelian randomization (MR) method to explore the putative causal relationships between 23 medications and the risk and progression of PD. We applied inverse-variance weighted meta-analysis (IVW) to combine MR estimates. Additionally, sensitivity analyses were conducted to evaluate the robustness of the results. Our genetic evidence suggests that thyroid preparations and calcium channel blockers reduce the risk of PD, and salicylic acid and derivatives slow the progression of PD motor symptoms. Additionally, genetic evidence also suggests that four medications were associated with PD risk or progression, but the sensitivity analysis revealed that three of the medications may have interference caused by reverse causality. Our findings suggest that there are weak causal relationships between several medications and the risk or progression of PD. Though further replication studies are needed to verify these findings, these new insights may help in understanding the etiology of the disease, generate new clues related to drug discovery, and quantify the risk of future drug intake.
引用
收藏
页数:11
相关论文
共 65 条
  • [1] Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
    AlDakheel, Amaal
    Kalia, Lorraine V.
    Lang, Anthony E.
    [J]. NEUROTHERAPEUTICS, 2014, 11 (01) : 6 - 23
  • [2] Diagnosis and Treatment of Parkinson Disease A Review
    Armstrong, Melissa J.
    Okun, Michael S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (06): : 548 - 560
  • [3] Drug repositioning: Identifying and developing new uses for existing drugs
    Ashburn, TT
    Thor, KB
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) : 673 - 683
  • [4] Drug Repurposing in Parkinson's Disease
    Athauda, Dilan
    Foltynie, Thomas
    [J]. CNS DRUGS, 2018, 32 (08) : 747 - 761
  • [5] Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
    Athauda, Dilan
    Maclagan, Kate
    Skene, Simon S.
    Bajwa-Joseph, Martha
    Letchford, Dawn
    Chowdhury, Kashfia
    Hibbert, Steve
    Budnik, Natalia
    Zampedri, Luca
    Dickson, John
    Li, Yazhou
    Aviles-Olmos, Iciar
    Warner, Thomas T.
    Limousin, Patricia
    Lees, Andrew J.
    Greig, Nigel H.
    Tebbs, Susan
    Foltynie, Thomas
    [J]. LANCET, 2017, 390 (10103) : 1664 - 1675
  • [6] G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson’s disease
    Barker R.A.
    Studer L.
    Cattaneo E.
    Takahashi J.
    G-Force PD consortium
    [J]. npj Parkinson's Disease, 1 (1)
  • [7] NSAID use and risk of Parkinson disease: a population-based case-control study
    Becker, C.
    Jick, S. S.
    Meier, C. R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (11) : 1336 - 1342
  • [8] Association Between Antiepileptic Drugs and Incident Parkinson Disease in the UK Biobank
    Belete, Daniel
    Jacobs, Benjamin M.
    Simonet, Cristina
    Bestwick, Jonathan P.
    Waters, Sheena
    Marshall, Charles R.
    Dobson, Ruth
    Noyce, Alastair J.
    [J]. JAMA NEUROLOGY, 2023, 80 (02) : 183 - 187
  • [9] Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms
    Blauwendraat, Cornelis
    Heilbron, Karl
    Vallerga, Costanza L.
    Bandres-Ciga, Sara
    von Coelln, Rainer
    Pihlstrom, Lasse
    Simon-Sanchez, Javier
    Schulte, Claudia
    Sharma, Manu
    Krohn, Lynne
    Siitonen, Ari
    Iwaki, Hirotaka
    Leonard, Hampton
    Noyce, Alastair J.
    Tan, Manuela
    Gibbs, J. Raphael
    Hernandez, Dena G.
    Scholz, Sonja W.
    Jankovic, Joseph
    Shulman, Lisa M.
    Lesage, Suzanne
    Corvol, Jean-Christophe
    Brice, Alexis
    van Hilten, Jacobus J.
    Marinus, Johan
    Eerola-Rautio, Johanna
    Tienari, Pentti
    Majamaa, Kari
    Toft, Mathias
    Grosset, Donald G.
    Gasser, Thomas
    Heutink, Peter
    Shulman, Joshua M.
    Wood, Nicolas
    Hardy, John
    Morris, Huw R.
    Hinds, David A.
    Gratten, Jacob
    Visscher, Peter M.
    Gan-Or, Ziv
    Nalls, Mike A.
    Singleton, Andrew B.
    [J]. MOVEMENT DISORDERS, 2019, 34 (06) : 866 - 875
  • [10] Parkinson's disease
    Bloem, Bastiaan R.
    Okun, Michael S.
    Klein, Christine
    [J]. LANCET, 2021, 397 (10291) : 2284 - 2303